跳至主要内容
临床试验/NCT01355276
NCT01355276已完成3 期

A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Eisai China Inc.13 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
400
试验地点
13
主要终点
Response rate of overall symptom improvement after 4-weeks treatment

研究概览

简要总结

The purpose of this study is to compare Cinitapride tablets with domperidone tablets (motilium), and to evaluate the efficacy and safety of Cinitapride tablets in the treatment of mild to moderate functional dyspepsia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

干预措施: Cinitapride (Drug)

2

Active Comparator

干预措施: domperidone (Drug)

结局指标

主要结局

Response rate of overall symptom improvement after 4-weeks treatment

时间窗: 4 weeks

次要结局

  • Percentage change of overall symptom score of functional dyspepsia from baseline after 2 and 4 weeks treatment(2 and 4 weeks)
  • Response rate after 2 weeks treatment(2 weeks)
  • Percentage change of individual symptom score (early satiety, discomfort with fullness after meal, flatulence, epigastric pain, epigastric burning, nausea, vomiting and belching) after 2 and 4 weeks treatment compared with the baseline(2 and 4 weeks)
  • Changes of gastric emptying in some patients after 4-week treatment(4 weeks)
  • Patient's global subjective assessment (Likert scale score) after 2 and 4 weeks treatment(2 and 4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验